Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has completed a non-dilutive 40 million dollar Secured Term Loan with Sagard Healthcare Partners. Saviuk telling Proactive that financing will now allow the company to support three new drugs that will transform the company. Saviuk said the company will have the Canadian license Xiidra and Simbrinza from Novartis Pharmaceuticals Canada, which are in the field of Ophthalmology and dry eyes. The money will also be used to for the acquisition of the Canadian license rights to Allerject from Kaleo which is a auto-injector for the treatment of serious allergic reactions.
Valeo Pharma closes 40-million-dollar financing to support 3 new drugs added to portfolio
